Clinical Trial Update: MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study [Phase 1]

View source ↗

Summary

Phase 1 study update for MEN1309 intravenous infusion in CD205-positive metastatic solid tumors and relapsed/refractory non-Hodgkin lymphoma; study terminated w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• MEN1309

Snippet

Sponsor: Menarini Group | Conditions: Metastatic Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 1 | Status: TERMINATED | Results posted: 2021-09-28